上海君實生物醫藥科技股份有限公司
Shanghai Junshi Biosciences Co., Ltd.*
( 於中華人民共和國註冊成立的股份有限公司 )
股份代號 : 1877
2024
中期報告
* 僅供識別
2
4
7
42
58
59
61
63
64
66
92
2
1
2 2
6
1
8
3
2
4
5
Roy Steven Herbst 7
1
5
6 11
Roy Steven Herbst 7
8 12
9 11
12
10
36
58 2 10 1003
5
16
8
348 5
985,689,871
219,295,700 H 766,394,171 A
6
8
3
H
200 H
H
16 17
H 01877
A 688180
www.junshipharma.com
1 2024 1 12 2024 6
21
2 2024 1 12 2024
6 21
3 2024 2 28
4 2024 6 21
5 2024 6 21
6 2024 6 21
7 2024 6 21
8 2024 6 21
9 2024 6 21
10 2024 6 21
11 2024 4 24
12 2024 4 24
4
2024 6 30 786 2023 17%
2023 11%
671 2023 50%
546 2023 42%
646 2023 351
35%
2024 6 30 3,311 2023 12
31 467
(ADCs)
3
30
20
2024 1 2023
3 6
COVID-19
8
5
2024 1 Coherus
LOQTORZI 2023 10 FDA 2023 12
NCCN
2024 1
HSA
2024 4 PMDA tifcemalimab BTLA TAB004/
JS004 (LS-SCLC)
III
2024 4 PCSK9 JS002 sNDA
NMPA
2024 4
sNDA
NMPA
2024 4
DO
2024 6
III
HEPATORCH NCT04723004 PFS OS
sNDA 2024 7 NMPA
2024 6
(ES-SCLC) sNDA
NMPA
2 0 24 6
P D - L1
CPS≥1 TNBC sNDA NMPA
GMP EC
2024 6 2023 2024 A 2024 H
6
6 30
2024 2023
%
786,056 669,703 17
575,255 381,190 51
(546,376) (948,599) (42)
(427,554) (373,126) 15
(252,599) (241,972) 4
(688,445) (1,125,338) (39)
(712,787) (1,163,516) (39)
(0.66) (1.01) (35)
(0.66) (1.01) (35)
2024 2023
6 30 12 31
%
6,186,979 5,812,637 6
4,820,897 5,549,827 (13)
11,007,876 11,362,464 (3)
2,053,426 1,547,100 33
2,331,030 2,475,156 (6)
4,384,456 4,022,256 9
6,623,420 7,340,208 (10)
7
first-in-class best-in-class
LOQTORZI JS001
NMPA PD-1 10
sNDA FDA
tifcemalimab (first-in-human)
BTLA FDA NMPA IND 2 III
Ib/II
(ADCs)
2024 786
17%
50%
671
50%
2024
3 6
PD-1
10
8
NMPA 36
NMPA NMPA
sNDA NMPA
2024 4
NMPA
2024 4
DO
2024 6
III
HEPATORCH NCT04723004 PFS OS
2024 7
sNDA
NMPA NMPA 36
2024 6
(ES-SCLC) sNDA NNPA
2024 6
PD-L1 CPS≥1
(TNBC) sNDA NMPA
2024 8
sNDA NMPA
9
2023 10 FDA 2024 1 Coherus
33 NCCN
(Project Orbis)
TGA HSA
TGA HSA
2024 7 EMA CHMP
EC CHMP
MHRA
Hikma Dr. Reddy ’ s
50
10
2024 4 PMDA tifcemalimab (LS-SCLC)
III J U S T A R -001
NCT06095583 BTLA
17
190 756
(FPI)
cHL tifcemalimab cHL
III (NCT06170489) tifcemalimab BTLA
III tifcemalimab
PD-(L)1 cHL 50
185
tifcemalimab Ib/II
2024 4 sNDA NMPA
NMPA
IL-17A JS005 III
11
Claudin18.2 ADC JS107 PI3K-α
JS105 CD20/CD3 JS203 PD-1/VEGF JS207 DKK1
JS015
2 NMPA GMP
4,500 9*500 2023 5 FDA
Pre-License Inspection PLI
EMA 2024 7 (The Ireland
Health Products Regulatory Authority) EMA CERTIFICATE OF GMP COMPLIANCE OF A
MANUFACTURER GMP GMP GMP
GMP
42,000 21*2,000 NMPA
EMA GMP
MAH
12
2,532 652
(license-in)
(ADCs)
3
30 20
13
2024 8 30
/
JS107 Claudin18.2 ADC JS015 DKK1 JS105 PI3K-α Tifcemalimab BTLA PD -1
JS003 PD-L1 JS203 CD3 CD20 JS207 PD-1 VEGF VEGF TNF-α
JS009 CD112R JS006 TIGIT JS007 CTLA-4 JS001sc PD-1 RdRp
JS019 CD39 JS012 Claudin 18.2 JS014 IL-21 1 S
PCSK9
JS110 XPO1 JS101 Pan-CDK JS108 Trop2 ADC JS005 IL-17A
JS113 EGFR 4th Gen JS111 EGFR exon 20 JS112 Aurora A
JS401 ANGPTL3 JS116 KRAS JS201 PD-1 TGF-β
JS103 Uricase JS010 CGRP JS026 S
UBP1213sc BLyS
1 FDA
2 IND
NCT03013101 2018 12 17 NMPA
NCT02915432 2021 2 NMPA 2023 10 FDA
NCT03113266 2021 4 NMPA
NCT03581786 2021 11 NMPA 2023 10 FDA
NCT03829969 2022 5 NMPA EMA MHRA
NCT03856411 EGFR 2022 9 NMPA
NCT04158440 2023 12 NMPA
NCT0 4394975 2024 4 NMPA
NCT04012606 2024 6 NMPA
JS001
NCT04085276 2024 6 NMPA
NCT04723004 sNDA NMPA
NCT03430297 sNDA NMPA
NCT03924050 EGFR TKI
NCT04848753
NCT04523493
NCT03859128
NCT05342194
NCT05302284
NCT05180734
14
15
TAB001/JS001
671 50%
PD-1 FDA
2
10
2018 12
2021 2
12
2021 4
2021 11
2022 5
16
EGFR ALK
2022 9
IIIA-IIIB
2023 12
2024 4
(ES-SCLC) 2024 6
PD-L1 CPS≥1
(TNBC) 2024 6
sNDA NMPA 2024 4 (DO)
CSCO CSCO CSCO
CSCO CSCO CSCO CSCO
CSCO
2024 1
3 6
PD-1
17
2023 10 2024 1
2024 7
(CHMP)
(EC) CHMP
(MHRA)
(TGA) (HSA)
15 40
18
2024 4
sNDA
NMPA
2024 4
DO
2024 6
III
HEPATORCH NCT04723004 PFS OS
2024 7
sNDA NMPA
2024 6
(ES-SCLC) sNDA
NMPA
2 0 24 6
P D - L1
CPS≥1 (TNBC) sNDA NMPA
2024 8
sNDA NMPA
19
vs
EGFR(-) NDA
vs vs
EGFR(+)
vs vs
vs vs vs
NDA
vs vs vs
vs vs vs
NMPA
BTD
vs vs vs
2024 1
HSA HSA
2024 7 CHMP
EC CHMP
20
2024 1 (nab-P) IV
(TNBC) III TORCHLIGHT ( Nature
Medicine , IF=58.7) TORCHLIGHT 2023 ASCO (LBA)
nab-P PFS
PD-L1 IV TNBC
2024 1 (GC/GEJC) II
(NEOSUMMIT-01) (Nature Medicine IF=58.7)
2023 ASCO
2024 1 (NSCLC) III
NEOTORCH ( Journal of the American Medical
Association JAMA IF=63.1) JAMA
NEOTORCH 2023 ASCO (ASCO Plenary
Series)4 ASCO EFS
2024 1 S C A L E -1
(ChiCTR2100045104) ( Journal for
ImmunoTherapy of Cancer , JITC, IF=10.3)
2024 1 II
(Nature ) (Nature Communication , IF=14.7)
(ORR) 95.7%
56.6% (CR) 1 2 PFS 95.7% 82.4% 4-5
(TRAE) 0
21
2024 1 II
INSIGHT Clinical Cancer Research IF=10.0
2024 2 II
(ESMO) Annals of
Oncology IF=56.7
33.3% (RFS) 11.7
2024 3 II
DNA(ctDNA) (bTMB)
Nature Communication IF=14.7
(The Lancet Oncology , IF=41.6)
2024 3 (nCRT)
(ESCC) Journal For Immunotherapy Of Cancer JITC IF=10.3
PD-1 ESCC
nCRT ESCC
(MPR) 78.9% (pCR) 47.4% nCRT
ESCC
22
2024 4 POLARIS-01 5
The Oncologist IF=4.8 POLARIS-01
PD-1
Clinical Cancer Research IF=10.0 POLARIS-01
(DOR) 15.6 (OS) 20 60 OS 28.5%
2024 6 (HCC) II
(Clinical Cancer Research , IF=10.0)
HCC RECIST v1.1 ORR
31.5% PFS 8.5 IRC mRECIST ORR 46.3% PFS 9.8
HCC 2022
ASCO GI
2024 6 (RCC) II
Journal For Immunotherapy Of Cancer JITC IF=10.3
2024 (AUA) PD33-07
2024 6 30 2024 ASCO
(I-O) I-O
23
Tifcemalimab TAB004/JS004
Tifcemalimab (first-in-human) B T
(BTLA) BTLA BTLA T B BTLA
HVEM Herpes virus entry mediator 2005 HVEM
TNF BTLA Tifcemalimab BTLA HVEM-BTLA
BTLA
Tifcemalimab III Ib/II
tifcemalimab III
JUSTAR-001 III
tifcemalimab
(LS-SCLC) BTLA
17 190
756
(FPI)
JS004-009-III-cHL (NCT06170489) III
tifcemalimab PD-(L)1
(cHL) BTLA III
50 185
tifcemalimab Ib/II
tifcemalimab
24
Tifcemalimab
(R/R)
2024 ASCO tifcemalimab
(ES-SCLC) I/II #8089
Ib/II (NCT05664971)
tifcemalimab
ES-SCLC tifcemalimab(200mg Q3W)
(240mg, Q3W) + 4 tifcemalimab
1 43 tifcemalimab
ORR 86.0% DCR 100% (DoR) 4.3
PFS 5.4 (OS) 2 97.7%
(TEAE) ≥3 TEAE 88.6% (irAE) 29.5% tifcemalimab
ES-SCLC
2024 ASCO tifcemalimab I
#2596 16
tifcemalimab(20mg 70mg 200mg 500mg Q3W)
(240mg Q3W) 75
(RCC) (NSCLC) (UC)5 tifcemalimab(200mg Q3W)
(240mg Q3W) 4 75.8% PD-
(L)1 18 ORR 17% DCR 39% RCC
11 ORR 18%, DCR 73% NSCLC 17 ORR 6%, DCR
42% UC 9 ORR 11% DCR 22% tifcemalimab
(IO)
tifcemalimab 2022 ASCO
tifcemalimab
25
Tifcemalimab
tifcemalimab+
tifcemalimab+ +
tifcemalimab+
tifcemalimab+ ±
tifcemalimab+
tifcemalimab+
tifcemalimab+
BTLA
tifcemalimab
tifcemalimab±
tifcemalimab±
tifcemalimab±
tifcemalimab±
tifcemalimab±
tifcemalimab+
tifcemalimab±
JT001/VV116
RdRp
RdRp
2023 1 28
NMPA COVID-19
2023
1 2024 1
26
2,300
UBP1211
2022 3
NMPA 2022 5 2022 11
NMPA
55
26
243 1,303
27
JS002
PCSK9 2
III 1
II 1 III
III
2024 4 sNDA NMPA
NMPA
2024 5 III
JS002-006 ( Nutrition Metabolism And
Cardiovascular Diseases ) 2024 6 III
JS002-003 (Journal of the American Heart Association )
28
IL-17A JS005
JS005 IL-17A JS005 IL-17
JS005
2023 (ACR) JS005 Ib/II
JS005 JS005
(p<0.0001) JS005 III
PD-1 VEGF JS207
JS207 PD-1 VEGF VEGF
PD-1 JS207 PD-1 VEGFA PD-1 PD-L1 PD-L2
VEGF VEGF
PD-1 VEGF
JS207
JS207
JS207 JS207 I
CD20 CD3 JS203
JS203 CD20 CD3 CD20 B
B CD3 T CD3 T
T JS203 CD20 CD3 T
CD3 CD20 T JS203
JS203 JS203 I
PI3K-α JS105
JS105 PI3K-α
(HR) -2(HER-2) PIK3CA
JS105
JS105 JS105
I/II
29
Claudin18.2 -MMAE JS107
JS107 Claudin18.2 -MMAE (Monomethy lauristatin E)
Claudin18.2 (ADCs) JS107
Claudin18.2 MMAE
JS107 (ADCC) (CDC)
MMAE JS107
JS107 JS107
I/II
30
1.
2024 6 30 786 2023 17% (i)
709 2023 11%
(ii)
52 (iii) 24
671 2023 50%
2.
546 2023 402 42%
286 193
42 25
2023 54% 16% 34% 2%
2023 12 31
(i)
(ii)
31
3.
428 2023 54 15%
236 175
17 2023
16% 18% 2023 17% 2023 12 31
4.
253 2023 11 4%
110 70 54
19
2023 4% 25% 9% 2023 30% 2023 12 31
32
5.
2024 6 30 3,311 2023 12
31 467
600
739 869
941 2023 12
31 1,067
6.
6 30
2024 2023
(712,787) (1,163,516)
– 16,659
(1,063) (2,068)
(713,850) (1,148,925)
33
6 30
2024 2023
(645,691) (996,421)
6 30
2024 2023
984,943,273 985,191,620
2024 6 30 136,844 A 2024 6 30
2023 2 A 2,818,231
2023 2 2 2023 6 30
2024 6 30
34
2023 12 31 480 2024 6 30 450
2023
45 60 2023 12 31 45 60
2024 2023
6 30 12 31
0 90 358,558 462,972
91 180 2,419 9,484
180 88,927 7,267
449,904 479,723
2023 12 31 1,706 2024 6 30 1,299
2024 2023
6 30 12 31
246,535 247,264
369,863 479,284
a 328,688 408,516
53,780 133,997
21,041 97,137
b 10,050 14,947
191,851 234,202
33,776 41,411
43,640 49,257
1,299,224 1,706,015
35
(a)
(b)
0 90 2023 12 31 0 90
2024 2023
6 30 12 31
0 30 103,774 60,582
31 60 35,237 33,363
61 180 29,314 72,400
180 78,210 80,919
246,535 247,264
36
2024 6 30 1,573 0.45% 0.85%
967 1.98% 3.40%
2024 6 30 1,617
1.98% 3.40% 0.45% 0.85%
2024 6 30 1,114
2.70% 4.00% 0.45% 0.85% 2024 6
30 2023 12 31 233
2024 6 30 2023 12 31
88 2024 6 30
923 0.55% 0.85%
i ii
iii iv
37
2024 6 30
2024 2023
6 30 12 31
612,492 630,372
137,941 140,683
750,433 771,055
802,216 539,391
483,111 120,135
761,409 700,751
493,790 374,908
2,540,526 1,735,185
2024 6 30 2023 12 31
2024 6 30
1,521 2023 12 31 2,011 24%
2024 7,500
100% 2024 6 30
2024 6 30
38
2020 A
2020 9 29 2020 A 2020 A
2020 11 16 2020 2020 A 2020 H
2020 A
2020 A
(a) 2020 A
(b) 2020 11 16 2020 A
1,933 28,519,000
(c) 2020 A 2020 11
16 2020 2020 A 2020 H
12 12
(d) 2020 A 35,648,000 A
A 4.65% 3.62% 2020 A
7,129,000 A 20%
A
(e) 1%
39
(f) 2020 A 2020 11 16
48
(g)
(1) 40% 12
24 (2)
30% 24 36
(3) 30% 36
48
(1) 50% 12
24 (2)
50% 24 36
(h) A 55.50
A A
55.50
(i) 2020 A A 2020 9 29
A 50% A 85.46 (ii) 20 60
120 A 50% 20 A 90.25
A 2020 7 15 A 55.50
40
(i) 2020 A
(j)
2024 1 1 2024 6 30 2020 A
2020 A
2020 A
2024
2024 6 30
1 1
(1) (2) (3)
2020 11 16 2021 11 16 55.50 820,000 492,000 – – – – 492,000
2024 11 15
2020 11 16 2021 11 16 55.50 1,560,000 906,000 – – – – 906,000
2024 11 15
(4)
2020 11 16 2021 11 16 55.50 820,000 472,000 – – – – 472,000
2024 11 15
2020 11 16 2021 11 16 55.50 2,000,000 1,200,000 – – – – 1,200,000
2024 11 15
2020 11 16 2021 11 16 55.50 820,000 472,000 – – – – 472,000
2024 11 15
2020 11 16 2021 11 16 55.50 270,000 162,000 – – – – 162,000
2024 11 15
41
2024
2024 6 30
1 1
(1) (2) (3)
2020 11 16 2021 11 16 55.50 80,000 43,000 – – – – 43,000
2024 11 15
(5)
2020 11 16 2021 11 16 55.50 80,000 48,000 – – – – 48,000
2024 11 15
2020 11 16 2021 11 16 55.50 22,069,000 6,406,584 – – – – 6,406,584
2024 11 15
28,519,000 10,201,584 – – 10,201,584
(1) 2020 11 16
(2) (1) 40% 12
24 (2) 30%
24 36 (3)
30% 36 48
(3) A 55.50
(4) 2024 6 21
(5) 2024 4 24
(6)
42
2024 6 30 66 91
14 8 1 5
2024 2 28
2024 6 21
2024 6 21
2024 6 21
Roy Steven Herbst 2024 6 21
2024 6 21
3
2024 6 21
2024 6 21
43
13.51B(1)
44
2024 6 30 XV
XV 7 8
352
(1) (1) (1)
(2)
A 88,346,018 (L) 11.53% 8.96%
H 2,600 (L) 0.00% 0.00%
A 129,978,568 (L) 16.96% 13.19%
(2)
(3)
A 956,000 (L) 0.12% 0.10%
(4)
A 127,020 (L) 0.02% 0.01%
(5)
A 512,000 (L) 0.07% 0.05%
(5)
A 8,608,000 (L) 1.12% 0.87%
(6)
A 1,200,000 (L) 0.16% 0.12%
(7)
A 7,774,500 (L) 1.01% 0.79%
(7)
A 196,643,786 (L) 25.66% 19.95%
H 2,600 (L) 0.00% 0.00%
(8)
A 172,000 (L) 0.02% 0.02%
(9)
A 12,060 (L) 0.00% 0.00%
H 41,200 (L) 0.02% 0.00%
(9)
H 41,654 (L) 0.02% 0.00%
1. L S P 2024 6 30
985,689,871 766,394,171 A 219,295,700 H
2. 2024 6 30 88,346,018 A 2,600 H 2020 A
492,000
45
(i)
2017 12 25 2017 2021 12
31 2017 108,297,768 A
41,060,000 A (ii)
2019 7 26 2019 2024 6 30
2019 21,680,800 A
2024 6 30 (i) 20%
4,372,144 A 2017 (ii)
40%
4,600,000 43,584,000 A 2017
86.28% 52,556,144 A
3. 2024 6 30 50,000 A 2020 A 906,000
4. 2024 6 30 127,020 A
5. 2024 6 30 8,608,000 A 2024 6 30
40,000 A 2020 A 472,000
6. 2024 6 30 2020 A 1,200,000
7. 2024 6 30 7,774,500 A 60%
86.28%
2017
8. 2024 6 30 172,000 A 172,000 A 10,000 A
2020 9 29 2020 A 2020 11 16 270,000
A 270,000 A 108,000 A 2022 11 16
162,000 A
9. 2024 6 30 12,060 A 41,200 H 41,654 H
2024 6 30
XV 352
46
2024 6 30
XV
2024 6 30
XV 2 3
336
(1) (2) (2)
(3) (4)
A 41,060,000 (L) 5.36% 4.17%
A 155,583,786 (L) 20.30% 15.78%
A 43,584,000 (L) 5.69% 4.42%
(4)
A 153,059,786 (L) 19.97% 15.53%
A 4,600,000 (L) 0.60% 0.47%
(4)
A 192,043,786 (L) 25.06% 19.48%
(4)
A 4,372,144 (L) 0.57% 0.44%
A 192,271,642 (L) 25.09% 19.51%
(4)
A 4,288,400 (L) 0.56% 0.44%
A 192,355,386 (L) 25.10% 19.51%
(4)
A 3,789,720 (L) 0.49% 0.38%
A 192,854,066 (L) 25.16% 19.57%
(4)
A 3,719,504 (L) 0.49% 0.38%
A 192,924,282 (L) 25.17% 19.57%
(4)
A 2,884,000 (L) 0.38% 0.29%
A 193,759,786 (L) 25.28% 19.66%
(5)
A 21,680,800 (L) 2.83% 2.20%
A 88,346,018 (L) 11.53% 8.96%
(6)
A 78,852,000 (L) 10.29% 8.00%
H 19,770,307 (L) 9.02% 2.01%
47
(1) (2) (2)
(6)
A 76,590,000 (L) 9.99% 7.77%
(6)
A 76,590,000 (L) 9.99% 7.77%
(6)
A 78,852,000 (L) 10.29% 8.00%
Loyal Valley Capital Advantage Fund II LP (7)(8)
H 11,344,613 (L) 5.17% 1.15%
Loyal Valley Capital Advantage Fund II H 11,344,613 (L) 5.17% 1.15%
Limited (7)
LVC Holdings Limited(7) H 11,344,613 (L) 5.17% 1.15%
LVC Management Holdings Limited (7)
H 11,344,613 (L) 5.17% 1.15%
LVC Innovate Limited H 19,770,307 (L) 9.02% 2.01%
LVC Bytes Limited (7)
Jovial Champion Investments Limited(7) H 19,770,307 (L) 9.02% 2.01%
Vistra Trust (Singapore) Pte. Limited (7)
H 19,770,307 (L) 9.02% 2.01%
Highbury Investment Pte Ltd(8) H 1,574,289 (L) 0.72% 0.16%
H 11,344,613 (L) 5.17% 1.15%
GIC (Ventures) Pte. Ltd. (8)
H 12,427,689 (L) 5.67% 1.26%
GIC Special Investments Private Limited (8)
H 12,427,689 (L) 5.67% 1.26%
GIC Private Limited(8) H 12,427,689 (L) 5.67% 1.26%
Hillhouse Capital Advisors, Ltd. (9)
H 11,400,000 (L) 5.20% 1.16%
H 46,092,000 (L) 21.02% 4.68%
H 50,440,600 (L) 23.00% 5.12%
H 10,947,946 (L) 4.99% 1.11%
12,503,584 (S) 5.70% 1.27%
48
1. L S P
2. 2024 6 30 985,689,871 766,394,171 A 219,295,700 H
3. 2024 6 30 41,060,000 A 2017
2017 155,583,786 A
87,854,018 A 2020 A 492,000
4. 2017 2017
A
5. 2019 2019
6. 2024 6 30 76,590,000 A
2,262,000 A
99.99%
76,590,000 A
A
7. 2024 6 30 Loyal Valley Capital Advantage Fund II LP LVC Fund II LVC Renaissance Fund LP LVC
Renaissance Fund 11,344,613 H 8,426,000 H Loyal Valley Capital Advantage Fund II
Limited LVC Fund II GP LVC Fund II H LVC Renaissance
Limited LVC Renaissance GP LVC Renaissance Fund H
LVC Fund II GP LVC Holdings Limited LVC Management Holdings Limited
LVC Management Holdings Limited LVC Fund II H
LVC Fund II GP LVC Renaissance GP LVC Innovate Limited LVC Bytes Limited LVC
Innovate Limited Jovial Champion Investments Limited Vistra Trust(Singapore)
Pte. Limited LVC Innovate Limited LVC Bytes Limited Jovial Champion
Investments Limited Vistra Trust (Singapore) Pte. Limited LVC Fund II LVC Renaissance Fund
H Vistra Trust (Singapore) Pte. Limited
LVC Fund II LVC Renaissance Fund 19,770,307 H
49
8. 2024 6 30 Highbury Investment Pte Ltd Highbury 1,574,289 H Highbury LVC
Fund II 45.16% LVC Fund II 11,344,613 H Highbury GIC (Ventures) Pte.
Ltd. GIC Ventures GIC Special Investments Private Limited GIC SIPL
GIC Private Limited GIC Private GIC Ventures GIC SIPL GIC Private
Highbury H
9. 2024 6 30 Hillhouse Capital Advisors, Ltd. Gaoling Fund, L.P. YHG Investment, L.P.
Gaoling Fund, L.P. YHG Investment, L.P. 10,715,000 H 685,000 H
1.
2.
50
3.
4.
2023
5.
51
6.
4+7
21
2024 6 30 985,689,871 766,394,171 A 815,871 219,295,700
H
52
H
2021 6 23 J.P. Morgan Securities plc
2021 6 16
36,549,200 H H 70.18
H 2021 6 16 H 70.65
2,104
(a)
(b)
2021 6 16
2021 6 23
2024 6 30 2024 6 30
2023 2024 2024
12 31 6 30 6 30
815 2 2 814 – 2024
6 30
1 – – 1 – 2022 12 31
285 – – 285 – 2022 6 30
1,003 – – 1,000 – 2022 12 31
2,104 2 2 2,100 –
53
(i) (ii)
136,844 A 0.0139%
A
2024 3 7 102,459 29.35 29.21 3,001
2024 6 19 34,385 29.14 29.03 1,000
136,844 4,001
2024 6 30 815,871 A 2023 9 15,030,000
388,445 2023 10 6,905,000 171,266 2023 12 4,956,000
119,316 2024 6 30
C1
C3
54
[2020]940
2020 7 A 1.00 8,713 55.50
4,836 339
4,497 A 2020 7 8 A
2023 2024 2024
12 31 6 30 6 30
1,200,000 – (16) 1,216,655 – 2022 12 31
700,000 – – 700,000 – 2020 12 31
800,000 – – 824,509 – 2022 6 30
1,796,978 233,768 44,221 1,610,586 189,820 2024
12 31
4,496,978 1
223,768 2
44,205 2
4,351,750 1
189,820 1 2
1. (i) (ii)
2. (i) 2024 6 30 (ii) 2023 12 31
55
A
[2022]2616 2022 12 2 17
A 1.00 7,000
53.95 3,777
32 3,745 A 2022
3 7 2022 3 7 2022 6 14 2024 5 30 A
2022 12 2 A 61.23 A
2023 2024 2024
12 31 6 30 6 30
3,464 3,077 146 533 2,931 2026 12 31
281 137 55 199 82 2026 12 31
3,745 3,214 201 732 3,013
56
2024 7
(The Ireland Health Products Regulatory Authority) EMA CERTIFICATE OF GMP
COMPLIANCE OF A MANUFACTURER GMP GMP
GMP GMP
2024 7 JS125 HDACs IND NMPA
2024 7
sNDA NMPA
2024 7 LOQTORZI CHMP
2024 8 30
5,000 100 5,000
100 1
200
50% 50% 4,918
2021 7 19 23 2024 8 30
2024 8
sNDA NMPA
2024 8 A 30
57
2024 8 30
Med-Fine Venture Fund I, L.P. Allied Pulse Investment Holding Limited
9.45% 30,597,800
14,000,000
9.45% 2024 8 30
2024 6 30
2024 8 30
*
58
SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
59 91 *
2024 6 30
34 34 34
2410
34
2024 8 30
59
2024 6 30
6 30
2024 2023
3 786,056 669,703
(210,801) (288,513)
575,255 381,190
4 34,473 92,153
5 (17,557) (21,183)
10,416 (1,122)
(546,376) (948,599)
(427,554) (373,126)
(252,599) (241,972)
(8,878) (2,057)
(19,347) (30,249)
(24,393) (14,548)
(8,334) (16,320)
(684,894) (1,175,833)
6 (3,551) 50,495
7 (688,445) (1,125,338)
FVTOCI (28,050) (60,569)
3,708 22,391
(24,342) (38,178)
(712,787) (1,163,516)
60
2024 6 30
6 30
2024 2023
(645,691) (996,421)
(42,754) (128,917)
(688,445) (1,125,338)
(670,033) (1,034,599)
(42,754) (128,917)
(712,787) (1,163,516)
9
(0.66) (1.01)
(0.66) (1.01)
61
2024 6 30
2024 2023
6 30 12 31
10 3,918,692 3,789,409
10 436,940 463,915
126,300 134,417
11 100,778 74,656
12 192,807 167,920
13 102,228 103,396
15 453,896 188,388
16 855,338 890,536
6,186,979 5,812,637
554,107 538,053
14 449,904 479,723
15 505,156 744,388
16 600,000 –
17 261 9,521
17 2,711,469 3,778,142
4,820,897 5,549,827
18 1,299,224 1,706,015
11,095 18,017
19 802,216 539,391
27,200 2,400
154,278 146,298
17,625 27,104
19,392 35,931
2,331,030 2,475,156
2,489,867 3,074,671
8,676,846 8,887,308
62
2024 6 30
2024 2023
6 30 12 31
19 1,738,310 1,195,794
149,999 181,064
20 155,597 152,791
9,520 17,451
2,053,426 1,547,100
6,623,420 7,340,208
21 985,690 985,690
22 (30,892) (26,891)
5,541,990 6,212,023
6,496,788 7,170,822
126,632 169,386
6,623,420 7,340,208
63
2024 6 30
2024 1 1 985,690 (26,891) 14,796,560 86,110 512,203 (180,535) 38,467 (9,040,782) 7,170,822 169,386 7,340,208
– – – – – – – (645,691) (645,691) (42,754) (688,445)
– – – – – – 3,708 – 3,708 – 3,708
– – – – – (28,050) – – (28,050) – (28,050)
– – – – – (28,050) 3,708 (645,691) (670,033) (42,754) (712,787)
A – (4,001) – – – – – – (4,001) – (4,001)
2024 6 30 985,690 (30,892) 14,796,560 86,110 512,203 (208,585) 42,175 (9,686,473) 6,496,788 126,632 6,623,420
2023 1 1 982,872 – 14,531,698 173,728 640,686 (96,664) 28,254 (6,759,158) 9,501,416 292,834 9,794,250
– – – – – – – (996,421) (996,421) (128,917) (1,125,338)
– – – – – – 22,391 – 22,391 – 22,391
– – – – – (60,569) – – (60,569) – (60,569)
– – – – – (60,569) 22,391 (996,421) (1,034,599) (128,917) (1,163,516)
– – – – (128,483) – – – (128,483) 128,483 –
2,818 – 190,531 (36,938) – – – – 156,411 – 156,411
– – – 17,111 – – – – 17,111 35 17,146
2023 6 30 985,690 – 14,722,229 153,901 512,203 (157,233) 50,645 (7,755,579) 8,511,856 292,435 8,804,291
64
2024 6 30
6 30
2024 2023
(869,253) (1,228,175)
24,984 60,831
(393,287) (201,017)
1,865 22
(93) (247)
3,725 787
(765,000) (1,230,000)
100,389 1,202,853
(2,426) (414)
– (26,570)
– 31,086
3,900 1,953
(30,000) –
150,000 –
(35,000) –
– 500
(940,943) (160,216)
65
2024 6 30
6 30
2024 2023
– (2,753)
(23,901) (23,785)
1,434,544 214,726
(634,028) (116,669)
(33,862) (17,998)
– 152,595
– 3,000
– 11,000
(4,001) –
738,752 220,116
(1,071,444) (1,168,275)
3,778,142 5,996,936
4,771 25,101
2,711,469 4,853,762
66
2024 6 30
1.
2012 12 27 2015 5
2015 8
833330 2018 12 24 H
1877 2020 5 8
A 2020 7 15 688180
34 .
67
2024 6 30
2.
2.1
2024 6 30
2023 12 31
2024 1 1
16
1
1
7
7
2.2
2024 1 1
20 20-40
10 10-15
5
3-5
3-5 3-10
2024 12 31
68
2024 6 30
3.
6 30
2024 2023
709,044 641,292
24,485 –
739 –
734,268 641,292
51,788 28,411
786,056 669,703
2024 6 30 7,429,000 2023
6 30 16,344,000
2023 6 30
69
2024 6 30
3.
6 30
2024 2023
745,213 630,937
23,786 38,766
17,057 –
786,056 669,703
4.
6 30
2024 2023
24,454 55,027
a 3,214 1,080
b 6,805 36,046
34,473 92,153
(a)
(b)
70
2024 6 30
5.
6 30
2024 2023
(31,696) (23,532)
1,063 2,068
(388) (324)
14,234 –
(770) 605
(17,557) (21,183)
2024 6 30 Excellmab Pte. Ltd. Excellmab
Excellmab 40% 14,234,000
71
2024 6 30
6.
6 30
2024 2023
CIT 749 (106,231)
1,634 –
1,168 55,736
3,551 (50,495)
25%
15%
8.84%
2024 6 30 743,000
1,634,000
2023 6 30
106,231,000
72
2024 6 30
7.
6 30
2024 2023
9,934 5,901
131,030 131,258
(27,833) (36,206)
(636) (4,594)
102,561 90,458
25,604 26,069
– (1,748)
25,604 24,321
(2,793) –
5,719 6,520
8,334 16,320
8,884,000
2023 6 30 36,357,000
160,568 281,898
62,511 57,681
576,000 567,862
47,131 47,168
– 17,146
623,131 632,176
(43,881) (47,025)
(4,009) (10,193)
575,241 574,958
73
2024 6 30
8.
2024 2023 6 30
2024 2023 6 30
9.
6 30
2024 2023
(645,691) (996,421)
6 30
2024 2023
984,943,273 985,191,620
2024 6 30 136,844 A 2024 6 30
2023 2 A 2,818,231
2023 2 2 2023 6 30
2024 6 30
74
2024 6 30
10.
266,722,000 2023 6 30
330,253,000 13,536,000 2023 6 30
4,533,000
1 3
4,593,000 2023 6 30
16,977,000 4,593,000 2023 6 30
16,977,000
11.
2024 2023
6 30 12 31
115,000 80,000
(14,222) (5,344)
100,778 74,656
2024 6 30
10,000,000 25,000,000
Anwita Biosciences, Inc.
50% 49%
75
2024 6 30
12.
2024 2023
6 30 12 31
265,684 211,961
(63,388) (44,041)
(9,489) –
192,807 167,920
2024 6 30 1 Excellmab 40%
23,723,000 2
30,000,000
13.
2024 6 30 102,228,000 2023 12 31
103,396,000
14.
45 60 2023 12 31 45 60
2024 2023
6 30 12 31
0 90 358,558 462,972
91 180 2,419 9,484
180 88,927 7,267
449,904 479,723
76
2024 6 30
15.
2024 2023
6 30 12 31
25,034 27,139
24,480 29,265
a 267,246 245,217
b 202,826 101,175
– 3,900
– 530
VAT c
26,785 134,194
226,590 57,948
189,167 339,167
962,128 938,535
(3,076) (5,759)
959,052 932,776
505,156 744,388
453,896 188,388
959,052 932,776
(a)
2024 6 30
2,793,000 2023 6 30
(b)
(c) 2024 6 30 26,785,000 2023 12 31
134,194,000 2024 6 30
226,590,000 2023 12 31
57,948,000
77
2024 6 30
16.
2024 2023
6 30 12 31
600,000 –
150,106 153,777
46,898 42,182
602,199 610,393
56,135 84,184
855,338 890,536
17.
261,000 2024 12
2023 12 31 9,521,000
2024 6 30 0.0001% 5.15% 2023 12 31
0.0001% 5.28%
78
2024 6 30
18.
2024 2023
6 30 12 31
246,535 247,264
369,863 479,284
a 328,688 408,516
53,780 133,997
21,041 97,137
b 10,050 14,947
191,851 234,202
33,776 41,411
43,640 49,257
1,299,224 1,706,015
(a)
(b)
79
2024 6 30
18.
0 90 2023 12 31 0 90
2024 2023
6 30 12 31
0 30 103,774 60,582
31 60 35,237 33,363
61 180 29,314 72,400
180 78,210 80,919
246,535 247,264
19.
2024 2023
6 30 12 31
923,142 868,364
1,617,384 866,821
2,540,526 1,735,185
802,216 539,391
483,111 120,135
761,409 700,751
493,790 374,908
2,540,526 1,735,185
(802,216) (539,391)
1,738,310 1,195,794
80
2024 6 30
19.
2024 6 30 1,573,119,000 2023 12 31 1,282,750,000
0.45% 0.85% 2023 12 31 0.45% 0.85%
2024 6 30 967,407,000 2023 12 31 452,435,000
1.98% 3.40% 2023 12 31 1.98% 3.35%
2024 2023
6 30 12 31
– 4,672
612,492 630,372
137,941 140,683
750,433 775,727
20.
21.
1.0
2023 1 1 982,871,640 982,872
23 2,818,231 2,818
2023 6 30 985,689,871 985,690
2024 1 1
2024 6 30 985,689,871 985,690
81
2024 6 30
22.
2024 6 30 A
2024 3 102,459 29.35 29.21 3,001
2024 6 34,385 29.14 29.03 1,000
136,844 4,001
2024 6 30 815,871 A 2023 9 15,030,000
388,445 2023 10 6,905,000 171,266 2023 12
4,956,000 119,316 2024 6 30
23.
A
2020 11 16 A A
A 28,519,000
2020 11 16 12 40%
2020 11 16 24 30%
2020 11 16 36 30%
82
2024 6 30
23.
A
A
2024 6 30
2024 2024
1 1 6 30
2020 11 16 2023 11 16 2024 11 15 6,159,540 – – 6,159,540
6,159,540
55.50 – – 55.50
2023 6 30
2023 2023
1 1 6 30
2020 11 16 2022 11 16 2023 11 15 6,130,740 – (2,088,696) 4,042,044
2020 11 16 2023 11 16 2024 11 15 6,159,540 – – 6,159,540
12,290,280 – (2,088,696) 10,201,584
4,042,044
55.50 – 55.50 55.50
83
2024 6 30
23.
A
2021 11 15 A A
A 7,129,000
2021 11 15 12 50%
2021 11 15 24 50%
A
A
2024 6 30
2024 2024
1 1 6 30
2021 11 15 2023 11 15 2024 11 15 2,418,850 – – 2,418,850
2,418,850
55.50 – – 55.50
84
2024 6 30
23.
A
2023 6 30
2023 2023
1 1 6 30
2021 11 15 2022 11 15 2023 11 15 2,418,850 – (729,535) 1,689,315
2021 11 15 2023 11 15 2024 11 15 2,418,850 – – 2,418,850
4,837,700 – (729,535) 4,108,165
1,689,315
55.50 – 55.50 55.50
2024 6 30 2023 6 30
16,659,000 2023 6 30
487,000
85
2024 6 30
24.
2024 2023
6 30 12 31
1,390,613 1,705,623
130,000 305,763
25.
86
2024 6 30
25.
2024 2023
6 30 12 31
5,380 5,380 IPO
11,518 6,802 2024 2024
IPO
2023
2023
P/R&D 28% P/
R&D 3.28
131,058 152,508
P/R&D 12% 2023
16% P/R&D 7.47 2023
9.82
150,106 153,777
87
2024 6 30
25.
2024 2023
6 30 12 31
21,380 24,054
P/R&D 25% 2023
25% P/R&D 2.8 2023
3.44
221,269 233,778 IPO
45,102 41,045 2024 2024
P/R&D 22% P/
R&D 3.5
2023 2023
IPO
88
2024 6 30
25.
2024 2023
6 30 12 31
9,381 10,000 2024 2024
2023 2023 IPO
2023
174,009 149,008
30,000 30,000
600,000 –
1,399,203 806,352
30,725 58,774
25,410 25,410 IPO
1,455,338 890,536
89
2024 6 30
25.
2024 1 1 37,592 153,777 451,385 642,754
– – 10,000 10,000
4,716 (3,671) (33,195) (32,150)
2024 6 30 42,308 150,106 428,190 620,604
2023 1 1 12,182 156,236 529,322 697,740
– – 40,000 40,000
– (2,853) – (2,853)
– 3,229 (30,995) (27,766)
2023 6 30 12,182 156,612 538,327 707,121
90
2024 6 30
26.
(a)
6 30
2024 2023
– 3,239
(b)
6 30
2024 2023
a 491 491
849 –
b 27,873 –
Excellmab 16,344 –
a
b 2024 6 30
12
91
2024 6 30
26.
(c)
6 30
2024 2023
28,859 23,973
– 3,849
404 487
29,263 28,309
92
A 1.00
2020 7 15
A A
Allink Biotherapeutics, Inc.
Allink Biotherapeutics Co., Limited
C1
cHL
CHMP (Committee for Medicinal Products for
Human Use)
622
Coherus Coherus BioSciences, Inc.
COVID-19
CSCO
DCR
DO
93
Dr. Reddy ’s Dr. Reddy’s Laboratories Limited
EC
EFS
EMA
FDA
GMP
HCC
HSA
H 1.00
H H 2018 12 24
H H
Hikma Hikma MENA FZE
94
IND
MHRA
C3
NCE
NDA
NCCN
NMPA
OS
PFS
36,549,200 H
PMDA
95
RdRp RNA RNA
Med-
Fine Venture Fund I, L.P. Allied Pulse Investment Holding Limited
2024 6 30
Rxilient Biotech Pte. Ltd.
571
2023 6 27
1.00 H A
sNDA
A 2020 7 15
96
TGA
TNBC
14,000,000
%
*